GERMANTOWN, Md., Aug. 7, 2019 /PRNewswire/ -- Neuralstem, Inc.
(Nasdaq: CUR) ("Neuralstem" or the Company") today announced
that on August 6, 2019, it received a
letter from the Office of General Counsel of The Nasdaq Stock
Market LLC ("Nasdaq") informing the Company that the Nasdaq
Hearings Panel (the "Panel") has granted the Company's request for
continued listing of the Company's stock on the Nasdaq Stock
Market.
The Panel found that the Company had (i) demonstrated compliance
with the bid price requirement and (ii) addressed the Panel's
questions regarding its stockholders' equity position and will
continue its listing and that the matter is closed.
About Neuralstem, Inc.
Neuralstem is a clinical-stage biopharmaceutical company
developing novel treatments for nervous system diseases of high
unmet medical need. The Company has two lead development
candidates:
- NSI-566 is a stem cell therapy being tested for treatment of
paralysis in stroke, Amyotrophic Lateral Sclerosis (ALS) and
chronic spinal cord injury (cSCI)
- NSI-189, is a small molecule in clinical development for major
depressive disorder and in preclinical development for Angelman
syndrome, irradiation-induced cognitive impairment, diabetic
neuropathy, and stroke
Neuralstem's diversified portfolio of product candidates is
based on its proprietary neural stem cell technology.
Forward-Looking Statements
This news release contains "forward-looking statements" made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
relate to future, not past, events and may often be identified by
words such as "expect," "anticipate," "intend," "plan," "believe,"
"seek" or "will." Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Specific
risks and uncertainties that could cause our actual results to
differ materially from those expressed in our forward-looking
statements include risks inherent in the development and
commercialization of potential products, uncertainty of clinical
trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of
our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Neuralstem's periodic reports, including its
Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and
Exchange Commission (SEC), and in other reports filed with the SEC.
We do not assume any obligation to update any forward-looking
statements.
Investor Contact:
Hibiscus Bioventures
josh@hibiscusbio.com
View original
content:http://www.prnewswire.com/news-releases/neuralstem-announces-nasdaq-hearings-panel-grants-request-for-continued-listing-300897755.html
SOURCE Neuralstem, Inc.